Loading…
Loading…
I actually want to double-click on business and consulting piece. It seems trends there still remain below historical trends
Are you guys seeing any change in the RFP or new bookings mix in terms of FSO versus FSP
You recently moved the CRM end of support date from September of 2030 to December '29. What were the key drivers there
Why you don't think trends could start moving in the right direction as these large pharma companies now have some more clarity
Can you elaborate on that? Is it stronger renewal activity, up momentum, or new logo wins
how were trends there compared to Q1? And broadly, what would you attribute some of the key drivers behind Crossix's performance
are you surprised by the pace at which these top twenty are coming through
did you guys come across, like, pharma executives having like, increased focus on ROI, budget priorities
Can you confirm whether it's an existing CRM customer or your new CRM customer